AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04828083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline IV
Description: Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
Study NCT06493331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talking Circle
Description: step 1 A round seating area is created with chairs. Questions addressing students' perspectives on therapeutic communication styles, the difficulties and conveniences in their communication, and the problems they experience.~step 2 An object that indicates the talking order will be determined (ball). This object will pass from hand to hand and determine the order of speaking.~A conversation is started and the students are asked about their thoughts and experiences regarding communication with the pediatric patient and their family with questions prepared by the researchers.~step 3 The student who does not want to talk can say 1 pass. In the next round, he is encouraged to speak.~When the sharing is completed, the experiences of the participants will be shared and group comments will be received.
Study NCT05976412 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Regional lymph node radiotherapy
Description: Regional lymph node radiotherapy
Study NCT05976412 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest/whole breast irradiation
Description: chest/whole breast irradiation
Study NCT05976412 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: chest/whole breast irradiation
Description: chest/whole breast irradiation
Study NCT05072600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg Q3W
Study NCT06447714 — intervention group
Intervention type: BEHAVIORAL
Intervention: smoke
Description: cotinine detection
Study NCT05549778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polaprezinc group
Description: Abiraterone plus Polaprezinc for 6 months
Study NCT05549778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Abiraterone, radio- or chemotherapy
Study NCT05117697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lateral subcutaneous sphincterotomy
Description: Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy.
Study NCT06032338 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CRC screening invitation not including the screening test.
Description: The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
Study NCT06032338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailing of FIT with invitation
Description: The invitation to CRC-PBOSP will contain the CRC screening test.
Study NCT06032338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information letter before invitation
Description: An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
Study NCT06330883 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prognosis
Description: survival/mortalite
Study NCT06491082 — intervention group
Intervention type: DRUG
Intervention: Cisplatin, Carboplatin, Paclitaxel, Docetaxel
Description: Solid cancer Patients receiving any one drug or in combination
Study NCT04631926 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hip Muscle Exercise
Description: Standardized 12-week hip muscle exercises focusing on the external hip rotators with progressive resistance
Study NCT04936841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)
Study NCT04936841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 therapy
Description: immunotherapy drug, monoclonal antibody
Study NCT04936841 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation
Description: radiation to relieve symptoms
Study NCT05001451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GDX012 Suspension for IV Infusion
Description: Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion
Study NCT04296097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)
Study NCT04296097 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DBS
Description: Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)
Study NCT05216757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iguratimod
Description: iguratimod, 25mg bid po.
Study NCT05216757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 1 tablet bid po.
Study NCT06102603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the biobased polyester cast
Description: long arm casting
Study NCT06102603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the synthetic fiberglass cast
Description: long arm casting
Study NCT05520645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: use etomidate for anesthesia induction in hysteroscopic surgery
Study NCT05520645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: use propofol for anesthesia induction in hysteroscopic surgery
Study NCT05955404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care
Description: This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
Study NCT05487339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: fascial plane injection guided by fluoroscopy device
Study NCT05033665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase water consumption
Description: The underhydrated individuals will be instructed to increase their water intake for one week in order to meet the following two criteria: a) urinate at least 7 times per day and b) have straw-like color urine. A 2-mile run will be completed before and after the 7-day intervention.
Study NCT05033665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintain adequate water consumption
Description: The subjects that are classified as euhydrated will be asked to maintain high water intake for one week to ensure proper hydration. A 2-mile run will be completed before and after the 7-day intervention.
Study NCT04311216 — intervention group
Intervention type: OTHER
Intervention: 3D movement analysis with surface electromyography
Description: Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
Study NCT05096351 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
Study NCT04813926 — intervention group
Intervention type: DRUG
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Follow clinical practice.
Study NCT05227872 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: POCUS
Study NCT05197413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arrae bloat supplement
Description: The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
Study NCT05975684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: 0.5 mg/kg/day up to 15 mg/day divided three times a day for 4 weeks
Study NCT05975684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a day for 4 weeks
Study NCT05510596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging with contrast injection
Description: Magnetic Resonance Imaging with contrast injection
Study NCT05510596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal
Description: Blood withdrawal : serum, plasma, cytokine assay
Study NCT05510596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological tests
Description: Neuropsychological tests
Study NCT05500001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Patients by Family Education in Psychotic Illness Group
Description: Psychoeducation for families supporting young adults with psychosis.
Study NCT05179369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care with Well-Mama Intervention
Description: The intervention involves: (1) a Well-Mama checklist on 5 topic areas aligned with leading causes of MM and SMM: (a) mental health/depression; (b) cardiovascular symptoms; (c) safety (e.g., guns at home and intimate partner violence); (d) opioid/substance abuse; and (e) social support, self-agency, and well-being; and (2) Community Doula Navigators (CDNs) who will: (a) conduct biweekly check-ins with pregnant and postpartum women using the Well-Mama List and make appropriate referrals to providers and other resources following check-ins; (b) attend select patient visits; (c) lead virtual pregnancy \& postpartum support groups; and (d) provide labor support.
Study NCT06420661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPACE for T1D
Description: school-partnered collaborative care model
Study NCT06420661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: routine diabetes care with optional monthly insulin dose adjustment
Study NCT06237218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COTID program
Description: COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
Study NCT05059236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788, Nubeqa)
Description: 300 mg per tablet, oral administration with food
Study NCT05059236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADT
Description: LHRH agonist/antagonist or orchiectomy
Study NCT05541029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live music
Description: Live Music. A board-certified music therapist will provide live music (singing with instrument accompaniment) of child preferred songs, per caregiver report, with the tempo entrained to the child's respiratory rate at intervention start and decreased as needed to facilitate relaxation, with a target tempo of 60-80 beats per minute (BPM). Song choices will be based on patient preferences, per caregiver report, and performed with relaxing characteristics (steady rhythm and volume)
Study NCT05541029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recorded music
Description: Recorded Music. MP3 players will be loaded with a recorded music playlist of the child's preferred songs, per caregiver report, and connected to two small speakers that are to be placed at either side of the head of the bed. Speakers will be tested with sound level meter and volume control set at 50-60 decibels. A member of the study team will stay at bedside throughout the recorded music condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
Study NCT05541029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual Care. A pharmacologic approach to ameliorating stress and pain in MV children is standard of care in CHP's PICU. CHP provides weight-based guidelines to aid clinical decisions on medications for sedation and analgesia. Bedside nurses assess the child's sedation and pain scores once an hour and administered PRN medications as needed, based on clinical judgement, using CHP's PICU weight-based guidelines. For example, if a child has a pain score of >1-2 above goal, guidelines suggest providing a fentanyl dose of 0.5 mcg/kg and assessing again in 1 hour. We will include usual care as a third condition to explore how our selected biomarkers vary over 20 min. without the addition of any musical stimuli. A member of the study team will stay at bedside throughout the usual care condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
Study NCT06007898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent self-help psychological resource
Description: A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet.
Study NCT03891849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Injection
Description: Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or intravenously (IV).
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV.
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase pegol
Description: Given IV.
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO (ETP, near-ETP, and MPAL only).
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV (T-LLy only).
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Description: Given Intrathecal (IT), Age adjusted.
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT.
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Given IV
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, PO or intramuscular (IM).
Study NCT06390319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO (participants intolerant to mercaptopurine).
Study NCT06575738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable semaglutide
Description: Subcutaneous weekly injectable semaglutide
Study NCT06575738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual postoperative care
Description: Usual postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.
Study NCT06575738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual postoperative care
Description: Usual postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.
Study NCT04687150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank
Study NCT04687150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colored water
Description: Colored water (placebo)
Study NCT04936243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOLLOW UP VISIT-TELEMEDICINE
Description: Routine follow up care conducted remotely with video-conferencing tools
Study NCT04936243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOLLOW UP VISIT-FACE TO FACE
Description: Routine follow up care conducted in person
Study NCT06653426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Butyrate (NaBu)
Description: Participants will self-administer Sodium Butyrate (NaBu) daily for 12 weeks. The study aims to evaluate the effect of NaBu on menstrual symptoms by comparing symptom severity before and during the intervention. Participants will maintain an electronic diary (eDiary) to record their daily symptom severity, which will be used to assess changes over time. Regular follow-ups will be conducted to monitor progress and address any side effects or concerns.
Study NCT05229926 — intervention group
Intervention type: DEVICE
Intervention: CareCube
Description: modular, disposable, negative pressure, isolation patient care system
Study NCT06589258 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Assessing maternal and lactational plasma CBD uptake at different stages of breastfeeding
Description: Determination of delta 9-tetrahydrocannabinol (THC) and its metabolites , and of cannabidiol and its metabolites in blood and breasts-milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Realization of THC/CBD ratio; qualitative research in mother's and breast-fed child's urine for the presence of cannabinoids (THC, CBD and its metabolites).
Study NCT05146284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL770
Description: Tablet
Study NCT06660264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist Personalized Medication Review (PMR)
Description: Pharmacist-provided review of current medications and assessment of potential medication related problems.
Study NCT06660264 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Discussion of Pharmacogenomic results during the PMR
Description: Return of pharmacogenomic results and discussion of impact on medications.
Study NCT06678438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided brachial plexus block
Description: The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block
Study NCT06678438 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haematoma Block
Description: Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices
Study NCT06618859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Participants will be advised to consume meals and calorie-containing drinks only during a window of 8 hours, to be self-selected by the participant and advised by the investigators based on their daily routine and eating habits during the run-in phase.
Study NCT06618859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants will be advised to keep the same eating rhythm and timing of meals per day during the intervention.
Study NCT05323591 — intervention group
Intervention type: DRUG
Intervention: Filgotinib
Description: Tablets are administered in accordance with the product label
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 1
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 2
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 3
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 4
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 5
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, dose 6
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Study NCT06715540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-261, pre-specified therapeautic dose X
Description: Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials